118897-99-7 Usage
General Description
5-Bromo-6-fluoroindoline-2,3-dione is a chemical compound with the molecular formula C8H3BrFNO2. It is a heterocyclic compound containing a five-membered ring with two nitrogen atoms and two carbonyl groups. 5-broMo-6-fluoroindoline-2,3-dione is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including anti-inflammatory and antifungal properties. Additionally, this compound has been investigated for its use in organic synthesis and material science applications. Its unique structure and properties make it a versatile and important chemical in various industrial and research contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 118897-99-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,8,8,9 and 7 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 118897-99:
(8*1)+(7*1)+(6*8)+(5*8)+(4*9)+(3*7)+(2*9)+(1*9)=187
187 % 10 = 7
So 118897-99-7 is a valid CAS Registry Number.
118897-99-7Relevant articles and documents
SYK INHIBITOR AND USE METHOD THEREFOR
-
Paragraph 0143; 0145, (2020/05/07)
Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF
-
Paragraph 1365; 1366, (2015/11/09)
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
